Lung cancer is the most common cancer worldwide, contributing for 13% of all cancer types1. 85% of lung cancers are non-small cell lung cancers (NSCLC), of which histologically adenocarcinoma is the most prevalent2. The prevalence of EGFR mutations in NSCLC is 10-15% in Western and up to 50% in Asian patients3. The most common EGFR mutations are the L858R mutation in exon 21 and deletions in exon 194.
The Idylla™ EGFR Mutation Assay allows detection of EGFR mutations directly from formalin-fixed paraffin-embedded (FFPE) tissue sections in approx. 2.5 hours with less than 2 minutes hands-on time.
- Directly on FFPE tissue sections
- Minimum 1 x 5 µm FFPE tissue section with ≥ 10% tumor cells
- Approx. 2.5 hours total turnaround time from sample to result
- Less than 2 minutes hands-on time
- Detection of 53 relevant mutations in exons 18, 19, 20 and 21
- Highly standardized
- An average sensitivity of ≤1 to ≤5% based on research data
- Contamination-controlled design
1Navani et al., Lancet Respir Med (2015)
2American Cancer Society. Global Cancer Facts & Figures 2nd Edition (2011)
3Cooper et al., Molecular biology of lung cancer. J Thorac Dis (2013)
4NCCN Guidelines on Non-Small Cell Lung Cancer Version 4.2016